IBBIS will collaborate with a diverse array of global stakeholders—from industry and governments to academia and philanthropy—to develop practical solutions for reducing risks at key points throughout the bioscience and biotechnology research and development lifecycle.
Initially, IBBIS will focus on developing biosecurity tools and best practices for DNA synthesis providers around the world, so they do not inadvertently sell the building blocks of dangerous pathogens to malicious actors. IBBIS will provide cutting-edge software, known as the international “Common Mechanism” for DNA synthesis screening. Developed by an international consortium of technical experts, the new software will help companies vet DNA synthesis orders and customers.
IBBIS’ scope of activities will expand over time in pursuit of its broader mission. Future activities may include: development of a biosecurity funders’ compact to make grant funds and investments conditional on robust biosecurity practices; work with publishers to strengthen biosecurity review of manuscripts in order to prevent sharing of information that could make it easier for malicious actors to engineer dangerous pathogens; and advising governments on guidelines, regulations, and incentives to strengthen biosecurity within their borders.
IBBIS’ activities will complement the important work of the World Health Organization, the Biological Weapons Convention, and other regional and international organizations.